What Is Larazotide Acetate?

1. How does larazotide work?

Tight junctions help control what passes between neighboring intestinal cells. Researchers call this the paracellular route. Zonulin-associated signaling can increase passage through that route, which is one reason it attracts interest in diseases involving an impaired gut barrier.

In Gopalakrishnan and colleagues’ 2012 experiments, larazotide prevented changes in barrier proteins and the cellular scaffolding caused by gluten fragments and other stimuli. It also reduced passage of a gluten fragment across cultured intestinal cells. Mouse experiments supported an effect on junction structure and inflammation.

The proposed benefit is reduced exposure of underlying immune tissue to material crossing an impaired barrier. Calling larazotide a “zonulin blocker” is shorthand for that research model. It does not mean the peptide digests gluten, removes every cause of intestinal inflammation or makes food intolerances interchangeable.

Celiac trials tested whether regulating the barrier could reduce symptoms in people whose immune system reacts to gluten. That population differs from healthy people seeking to “optimize” their gut.

2. What do the human celiac trials show?

The trials tested different conditions. Some deliberately exposed participants to gluten; another enrolled people with persistent symptoms while maintaining their gluten-free diet.

How large was the Phase 2 benefit?

The 2015 trial reported 26% fewer symptomatic days with the lowest dose versus placebo. This was an exploratory endpoint; the primary endpoint was a celiac symptom-scale score, which also favored that dose (p = 0.022). Participants continued their gluten-free diet.

The percentage describes days meeting the study’s symptom threshold. It cannot be read as “26% gut repair” or a 26% chance of curing celiac disease. The trial also gives no basis for expecting better results from increasing the dose.

3. Why was the Phase 3 larazotide trial stopped?

In its June 21, 2022 announcement, 9 Meters Biopharma said an independent interim analysis estimated that too many additional participants would be needed to demonstrate a statistically significant clinical effect. The study had planned to enroll 525 people. The company’s annual report subsequently confirmed discontinuation of larazotide development for celiac disease.

The cited announcement does not identify a newly discovered toxicity as the reason for stopping, and it does not provide a complete final efficacy analysis.

“Reached Phase 3” describes how far testing progressed. It leaves out whether the trial confirmed benefit. For larazotide, the earlier positive symptom result never gained confirmation from a completed successful Phase 3 celiac trial.

Larazotide remains investigational as of September 22, 2026. The FDA’s larazotide acetate substance record includes the agency’s explicit notice that a substance identifier does not imply regulatory review or approval.

4. Does larazotide help leaky gut, IBS or bloating?

The celiac studies do not establish a treatment for IBS, SIBO, food sensitivity or unexplained bloating. Those labels describe different problems, and a response in celiac disease cannot identify who would benefit outside that population.

Even the permeability measurements require care. The early trials used a urine test comparing passage of two sugars, lactulose and mannitol. In the 2012 trial, measurements varied enough to prevent a clear assessment of the drug’s effect on permeability. In the 2013 study, symptom and antibody findings were more favorable than the permeability result.

For a person tracking digestive symptoms, a lower bloating score cannot reveal which biological process changed. Diet, bowel habits and other treatments can change at the same time. A symptom record is useful for describing a pattern; it cannot diagnose a damaged intestinal barrier or prove that it healed.

Can a zonulin test tell you whether larazotide is working?

A 2018 study by Scheffler and colleagues examined a widely used commercial zonulin assay. It did not detect pre-haptoglobin 2, the protein commonly identified as zonulin; the researchers identified properdin as a possible alternative target.

That finding concerns the assay they tested, rather than proving every zonulin test is invalid. It does mean that a report labeled “zonulin” needs method-specific validation before its number can be treated as a direct measurement of intestinal permeability. A falling result alone cannot establish a larazotide response.

5. Oral larazotide vs injections, dosage and half-life

The Phase 3 formulation contained enteric-coated beads inside gelatin capsules. The coating was part of an intestinal delivery system. An ordinary capsule or injectable vial cannot inherit that formulation’s trial evidence from sharing the ingredient name.

The trial compared 0.25 and 0.50 mg orally three times daily with placebo. These doses describe research exposure, not a validated self-treatment schedule. There is no established larazotide cycle for healthy users or evidence-based conversion from oral dosing to injection.

In the 2012 study, blood concentrations remained below the assay’s quantification limit of 0.5 ng/mL. That fits a locally acting intestinal treatment. Systemic bioavailability, the amount reaching the circulation, is therefore a poor standalone measure of whether this formulation reaches its intended target.

Those undetectable blood levels also cannot supply a dependable plasma half-life for planning injections or predicting intestinal effects. The duration of local activity needs its own measurements.

Researchers have explored why dose-response may be uneven. In Slifer and colleagues’ 2021 pig-intestine experiments, one concentration improved barrier recovery after ischemic injury, while lower and higher concentrations did not. A breakdown fragment inhibited the parent peptide’s effect. This offers a laboratory hypothesis for reduced activity at higher exposure; it does not establish why particular human trial doses failed.

6. Larazotide side effects and safety

In the 86-person trial, investigators judged adverse events potentially related to study medication in 25.0% of larazotide recipients and 26.9% of placebo recipients. Headache was common across groups, and no serious adverse events occurred. Gastrointestinal complaints also contributed to some withdrawals.

This supports short-term tolerability under those study conditions. It does not establish that every symptom was caused by larazotide, or that repeated exposure over years is safe. Nor can oral safety observations establish the risks of a different route.

The human evidence applies to defined trial products. A commercial research product introduces separate questions about identity, amount, impurities and delivery. An acetate label does not establish equivalence to the capsules used in a clinical trial. The research reviewed here also provides no validated safety profile for combining larazotide with several other experimental peptides.

7. Larazotide for long COVID and MIS-C

A 2025 randomized trial by Yonker and colleagues tested larazotide in 12 hospitalized children with MIS-C, a serious inflammatory condition following SARS-CoV-2 infection. Larazotide was added to standard care. Researchers reported faster clearance of circulating spike antigen, faster improvement in gastrointestinal symptoms and earlier return to usual activities. They reported no larazotide-related adverse events during follow-up.

The sample was small, and the participants had an acute pediatric inflammatory illness. These results cannot establish treatment of adult long COVID, routine brain fog or persistent fatigue from other causes.

A separate Phase 2 long-COVID trial, NCT05747534, enrolled 107 participants and completed on June 18, 2026. Its August 2026 registry update lists completion, but no results were posted when checked on September 22, 2026. Completion means the trial finished; it does not tell us whether symptoms improved more than with placebo.

8. Larazotide vs KPV and BPC-157

These peptides appear in overlapping gut-health discussions, but the research differs enough that calling them interchangeable would hide more than it explains.

The cited larazotide trials do not test a larazotide/KPV/BPC-157 stack. Separate mechanisms cannot establish an additive benefit or a safe combination. Changing all three alongside a new diet would also make a personal before-and-after comparison difficult to interpret.

For the next long-COVID report, look for the treatment-versus-placebo difference in symptoms and daily function, the number of participants analyzed, and adverse events in both groups. Changes in circulating antigen would add biological context; patients still need to know whether they felt and functioned better.

9. Larazotide Acetate FAQ

• Is larazotide acetate the same as AT-1001?

  Yes. AT-1001, AT1001 and INN-202 are research names for larazotide. Acetate identifies its salt form.

• Does larazotide heal leaky gut?

  Laboratory studies support an effect on intestinal tight junctions. Human celiac trials found some symptom benefits but did not consistently demonstrate improved permeability. Benefits for healthy people with self-described leaky gut remain unestablished.

• What larazotide dosage has been studied?

  The terminated Phase 3 celiac trial compared oral capsules containing 0.25 or 0.50 mg three times daily with placebo. These are research doses, not an approved treatment schedule or a validated treatment plan for general gut health.

• Is larazotide taken orally or injected?

  The celiac trials used oral preparations intended to act locally in the intestine. Their results cannot establish the effectiveness or safety of an injectable product.

• What are the side effects of larazotide?

  Headache and gastrointestinal complaints occurred in early trials. Events also occurred with placebo, so reporting an event does not prove the drug caused it. Long-term safety and the safety of commercial research products remain uncertain.

• Why was the larazotide Phase 3 trial stopped?

  The sponsor reported that the additional enrollment needed to demonstrate a statistically significant clinical effect was too large to support continuing. The registry records 307 enrolled participants and termination by the sponsor.

• Does larazotide treat long COVID?

  A 107-participant Phase 2 trial completed in June 2026, but its registry had no results posted as of September 22, 2026. A small positive trial in children with MIS-C studied a different condition and cannot establish an adult long-COVID benefit.

• Is larazotide acetate FDA-approved?

  Larazotide remains investigational, with no FDA-approved treatment use identified as of September 22, 2026. An FDA substance identifier or permission to conduct a trial is not drug approval.

10. Sources